Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Novartis receives new CHMP backing for Lucentis

Novartis receives new CHMP backing for Lucentis

3rd June 2013

Novartis' Lucentis has been recommended for European approval for use among patients with visual impairment due to choroidal neovascularisation (CNV) secondary to pathologic myopia.

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has endorsed Lucentis for this application based on clinical evidence showing that it can deliver visual acuity improvements and a superior performance to the standard of care.

CNV is the most common vision-threatening complication of high myopia, usually affecting patients younger than 50 years old and leading to 90 percent of patients developing severe vision loss after five years if left untreated.

Current therapy options focus on stabilising vision and prevent further loss, meaning Lucentis could represent a major advancement in care quality.

Tim Wright, global head of development at Novartis Pharmaceuticals, said: "A treatment with the long-term safety profile of Lucentis that actually improves and maintains vision with just a few injections would be of great benefit."

Last month, the company reported data from real-world studies of Lucentis demonstrating its strong proven performance across a range of indications.ADNFCR-8000103-ID-801593404-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.